Company Overview
Aethlon Medical develops immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses, the Aethlon Hemopurifier® reduces the presence of circulating viruses in infected individuals. The technology provides a first-line candidate defense against viruses that are not addressed with proven drug therapies, including natural occurring pandemic threats and agents of bioterrorism. The Hemopurifier® can also be deployed as a strategy to improve the benefit of approved antiviral drug regimens. At present, the Hemopurifier® is being advanced in the United States under an FDA approved clinical study. Aethlon Medical is also investigating the potential use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients. Aethlon Medical is also the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE). ESI's TauSome™ biomarker is being clinically evaluated as the basis for a blood-based test to identify CTE in living individuals.

Aethlon Announces Reverse Stock Split
Oct 14 2019, 3:55 PM EDT

Aethlon Medical Announces FDA Approval Of IDE For Oncology Indications
Oct 7 2019, 8:31 AM EDT

Aethlon Medical Receives Extension from Nasdaq to Regain Compliance with Continued Listing Requirements
Oct 3 2019, 8:31 AM EDT

Stock Overview
Symbol: AEMD
Exchange: Nasdaq
Market Cap: 78.77m
Last Price: $3.95
52-Week: $3.0375 - $26.10
10/23/2019 04:00 PM EDT

Investor Relations
Aethlon Medical, Inc.
Jim Frakes
CFO
9635 Granite Ridge Dr.
Suite 100
San Diego, CA 92123
jfrakes@aethlonmedical.com

Management Team
Timothy C. Rodell, M.D., FCCP
Interim Chief Executive Officer and Director

James B. Frakes
Chief Financial Officer and Senior Vice President – Finance

Michael Jacobs
Senior Scientist

Annette Marleau, PhD
Director of Research

Lisa M. Boswell
Director, Quality Systems and Regulatory Affairs

Disclaimer
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.